Study S003223

A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06064006
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 125
Start: 2023-09-15
Primary completion: 2024-11-27
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight
Interventions: DRUG:NNC0487-0111; DRUG:Placebo (NNC0487-0111)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1289-3282

Registered primary outcomes

PART A: Number of treatment emergent adverse events (TEAE) [From pre-dose on Day 1 until completion of the end of study visit, up to Day 25]
PARTS B to E: Number of treatment emergent adverse events (TEAE) [From pre-dose on Day 1 until completion of the end of study visit (V37) up to Day 270]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013019	Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Dahl K, Lancet (London, England)	2025	Randomized trial	PMID 40550231 DOI	cites ClinicalTrials.gov:NCT06064006; registry reference DERIVED:40550231
R0038416	2002-LB: Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist—Results of a Phase 1b/2a Clinical Trial Kirsten Dahl, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06064006